VEGFA Recombinant Antibody, APC-Cy7 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bsm-63036r-apc-cy7 |
| Product Name | VEGFA Recombinant Antibody, APC-Cy7 Conjugated |
| Applications |
IF(IHC-P)
|
| Reactivity | Human |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human VEGF |
| Clonality | Recombinant |
| Isotype | IgG |
| Concentration | Lot dependent |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Secreted |
| Synonyms | Vascuoar endothelial growth factor A; VEGF A; vascular endothelial growth factor A isoform 2 precursor; MGC70609; MVCD1; VEGF; VPF; VEGFA_HUMAN; VEGF-A; Vascular permeability factor (VPF); |
| Background | Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
| Application Dilution | |
| IF(IHC-P) | 1:100-500 |